Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SwitzerlandIPO:
19 October 2016Website:
http://www.crisprtx.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:55:12 GMTDividend
Analysts recommendations
Institutional Ownership
CRSP Latest News
Imagine this: you walk into a hospital for a procedure. You expect a long, traditional surgery with a lengthy recovery.
Biotech stocks to buy now reflect a more dynamic shift in investor focus of late.Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Global vaccine sales for the crippling virus were upwards of $142 billion from 2020 to 2023.
In the world of investing, biotech stocks represent a unique blend of high risk and high reward. After a period of volatility in the broader markets in 2022 and 2023, biotech stocks are now drawing attention for their potential to deliver substantial long-term returns.
CRISPR Therapeutics AG (CRSP) closed at $56.63 in the latest trading session, marking a +1.22% move from the prior day.
Chasing the next trend thing after AI is easier said than done. It is also a pretty risky strategy.
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRISPR Therapeutics AG (CRSP) reachead $59.60 at the closing of the latest trading day, reflecting a -1.6% change compared to its last close.
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics AG (NASDAQ:CRSP ) Company Conference Call June 11, 2024 9:20 AM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon everyone, thank you for joining us. Really pleased to have Sam Kulkarni, CEO of CRISPR Therapeutics here with us.
Cathie Wood loves bargains on potential long-term winners -- especially when the company is an innovator. One of her favorite technologies in healthcare is gene editing, and she's been loading up on two stocks in particular.
What type of business is CRISPR Therapeutics AG?
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
What sector is CRISPR Therapeutics AG in?
CRISPR Therapeutics AG is in the Healthcare sector
What industry is CRISPR Therapeutics AG in?
CRISPR Therapeutics AG is in the Biotechnology industry
What country is CRISPR Therapeutics AG from?
CRISPR Therapeutics AG is headquartered in Switzerland
When did CRISPR Therapeutics AG go public?
CRISPR Therapeutics AG initial public offering (IPO) was on 19 October 2016
What is CRISPR Therapeutics AG website?
https://www.crisprtx.com
Is CRISPR Therapeutics AG in the S&P 500?
No, CRISPR Therapeutics AG is not included in the S&P 500 index
Is CRISPR Therapeutics AG in the NASDAQ 100?
No, CRISPR Therapeutics AG is not included in the NASDAQ 100 index
Is CRISPR Therapeutics AG in the Dow Jones?
No, CRISPR Therapeutics AG is not included in the Dow Jones index
When does CRISPR Therapeutics AG report earnings?
The next expected earnings date for CRISPR Therapeutics AG is 07 August 2024